QBI, a wholly owned subsidiary of Quark Pharmaceuticals, will head an Israeli consortium of industry and academic collaborators focused on developing "novel genetic technologies in the field of RNAi," the company said in a filing with the US Securities and Exchange Commission last month.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Browse our free articlesYou can still register for access to our free content.